The obesity treatment landscape sees mixed results with new therapies. Eli Lilly's oral GLP-1 agonist orforglipron showed significant but lower-than-expected weight loss in Phase 3 trials, trailing behind injectable competitors like Novo Nordisk's Wegovy. Despite this, the company remains optimistic about orforglipron's role in obesity management and maintenance. Concurrently, Minghui Pharmaceutical raised $131 million in a pre-IPO round to advance its PD-1/VEGF bispecific antibody and ADC pipeline. Market dynamics also reveal ongoing competition and challenges, as Novo Nordisk faces rising threats from new compounds and compounding practices. These developments underscore intense innovation and competition in metabolic disease therapeutics.